● TIER 3 — Information onlyGRADE A (efficacy) — unapprovedGLP-1 / incretins & amylin
Retatrutide
GIP/GLP-1/glucagon triple agonist. Research verification: Yes (TGA pending). 2 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Investigational; Lilly submission planned (reported Q1 2027).
Compounding (503A/503B)
Not compoundable; 'research' sales are illegal unapproved drugs.
DEA
Not controlled.
WADA (sport)
S0 Non-approved substances
Mechanism
Triple agonist; t½ ~6 d.
Human evidence · 2
Phase 3 TRIUMPH-1 (NEJM 2026): ~25% at 80 wk on 12 mg (per publication summary). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Phase 2, n=338: −24.2% at 48 wk (12 mg). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Reference only. This page summarizes publicly available regulatory and research information about Retatrutide. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.